Skip to main content

Table 1 Clinicopathological patient’s characteristics

From: Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

 

Arm A

(n = 66)

Arm B

(n = 65)

Age (years)

 Median (range)

54 (33–78)

57 (33–72)

ECOG PS

 Unknown

1 (2%)

 

 0–1

65 (99%)

65 (100%)

N° CT regimens

 1st line

47 (71%)

46 (71%)

 2nd-3rd line

19 (29%)

19 (29%)

ER status

 Positive

43 (65%)

38 (58%)

 Negative

23 (35%)

27 (42%)

Adjuvant Anthracyclines

 No

39 (59%)

44 (68%)

 Yes

27 (41%)

21 (32%)

Endocrine therapy

 No

14 (21%)

16 (24%)

 Adjuvant

19 (29%)

24 (37%)

 Palliative

8 (12%)

8 (12%)

Disease sites

 Bone only

6 (9%)

10 (15%)

 Visceral only

20 (30%)

31 (48%)

 Visceral + bone

24 (36%)

12 (18%)

Advanced disease at diagnosis (pM1)

21 (32%)

24 (37%)